Nicotine, but neither the α4β2 ligand RJR2403 nor an α7 nAChR subtype selective agonist, protects against a partial 6-hydroxydopamine lesion of the rat median forebrain bundle

Neuropharmacology

Volumn 51, Issue 3, 2006, Pages 506-516

  Visanji, N P ^a   O'Neill, M J ^b   Duty, S ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

nAChR; Neuroprotection; Nicotine; Nigrostriatal tract; Parkinson's disease

Indexed keywords

1 AZABICYCLO[2.2.2]OCT 3 YL 5 (2 PYRIDYL)THIOPENE 2 CARBAMIDE; AMPHETAMINE; N METHYL 4 (3 PYRIDINYL) 3 BUTENAMINE; NICOTINE; NICOTINIC AGENT; OXIDOPAMINE; SODIUM CHLORIDE; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; 2,2 DIFLUORO 1 (TRIFLUOROMETHYL)VINYL FLUOROMETHYL ETHER; DRUG DERIVATIVE; ETHER DERIVATIVE; FLUORINATED HYDROCARBON; FLUOROMETHYL 2,2-DIFLUORO-1-(TRIFLUOROMETHYL)VINYL ETHER; INHALATION ANESTHETIC AGENT; METANICOTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; IMMUNOREACTIVITY; MALE; MEDIAL FOREBRAIN BUNDLE; NERVE LESION; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PRIORITY JOURNAL; RAT; ANALYSIS OF VARIANCE; ANIMAL; BRAIN INJURY; CELL COUNT; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DOSE RESPONSE; DRUG INTERACTION; IMMUNOHISTOCHEMISTRY; INJURY; METABOLISM; METHODOLOGY; PATHOLOGY; SPRAGUE DAWLEY RAT;

ANALYSIS OF VARIANCE; ANESTHETICS, INHALATION; ANIMALS; BRAIN INJURIES; CELL COUNT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ETHERS; HYDROCARBONS, FLUORINATED; IMMUNOHISTOCHEMISTRY; MALE; MEDIAL FOREBRAIN BUNDLE; NICOTINE; NICOTINIC AGONISTS; OXIDOPAMINE; RATS; RATS, SPRAGUE-DAWLEY; TYROSINE 3-MONOOXYGENASE;

EID: 33747360178     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2006.04.015     Document Type: Article

References (55)

1. Abin-Carriquiry J.A., McGregor-Armas R., Costa G., Urbanavicius J., and Dajas F. Presynaptic involvement in the nicotine prevention of the dopamine loss provoked by 6-OHDA administration in the substantia nigra. Neurotoxicity Research 4 (2002) 133-139
2. Baron J.A. Beneficial effects of nicotine and cigarette smoking: the real, the possible and the spurious. British Medical Bulletin 52 (1996) 58-73
3. Behmand R.A., and Harik S.I. Nicotine enhances 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. Journal of Neurochemistry 58 (1992) 776-779
4. Belluardo N., Mudo G., Blum M., and Fuxe K. Central nicotinic receptors, neurotrophic factors and neuroprotection. Behavioural Brain Research 113 (2000) 21-34
5. Bencherif M., Lovette M.E., Fowler K.W., Arrington S., Reeves L., Caldwell W.S., and Lippiello P.M. RJR-2403: a nicotinic agonist with CNS selectivity I. In vitro characterization. Journal of Pharmacology and Experimental Therapeutics 279 (1996) 1413-1421
6. Berger F., Gage F.H., and Vijayaraghavan S. Nicotinic receptor-induced apoptotic cell death of hippocampal progenitor cells. Journal of Neuroscience 18 (1998) 6871-6881
7. Borlongan C.V., Shytle R.D., Ross S.D., Shimizu T., Freeman T.B., Cahill D.W., and Sanberg P.R. (-)-Nicotine protects against systemic kainic acid-induced excitotoxic effects. Experimental Neurology 136 (1995) 261-265
8. Brooks D.J., Frey K.A., Marek K.L., Oakes D., Paty D., Prentice R., Shults C.W., and Stoessl A.J. Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease. Experimental Neurology 184 Suppl. 1 (2003) S68-S79
9. Champtiaux N., Gotti C., Cordero-Erausquin M., David D.J., Przybylski C., Lena C., Clementi F., Moretti M., Rossi F.M., Le Novere N., McIntosh J.M., Gardier A.M., and Changeux J.P. Subunit composition of functional nicotinic receptors in dopaminergic neurons investigated with knock-out mice. Journal of Neuroscience 23 (2003) 7820-7829
10. Cilia J., Cluderay J.E., Robbins M.J., Reavill C., Southam E., Kew J.N., and Jones D.N. Reversal of isolation-rearing-induced PPI deficits by an alpha7 nicotinic receptor agonist. Psychopharmacology (Berl) 182 (2005) 214-219
11. Cormier A., Morin C., Zini R., Tillement J.P., and Lagrue G. In vitro effects of nicotine on mitochondrial respiration and superoxide anion generation. Brain Research 900 (2001) 72-79
12. Costa G., Abin-Carriquiry J.A., and Dajas F. Nicotine prevents striatal dopamine loss produced by 6-hydroxydopamine lesion in the substantia nigra. Brain Research 888 (2001) 336-342
13. Dass B., Iravani M.M., Huang C., Barsoum J., Engber T.M., Galdes A., and Jenner P. Sonic hedgehog delivered by an adeno-associated virus protects dopaminergic neurones against 6-OHDA toxicity in the rat. Journal of Neural Transmission 112 (2005) 763-778
14. Fahn S., Oakes D., Shoulson I., Kieburtz K., Rudolph A., Lang A., Olanow C.W., Tanner C., and Marek K. Levodopa and the progression of Parkinson's disease. New England Journal of Medicine 351 (2004) 2498-2508
15. Ferger B., Spratt C., Earl C.D., Teismann P., Oertel W.H., and Kuschinsky K. Effects of nicotine on hydroxyl free radical formation in vitro and on MPTP-induced neurotoxicity in vivo. Naunyn Schmiedebergs Archives of Pharmacology 358 (1998) 351-359
16. Garrido R., Malecki A., Hennig B., and Toborek M. Nicotine attenuates arachidonic acid-induced neurotoxicity in cultured spinal cord neurons. Brain Research 861 (2000) 59-68
17. Garrido R., Mattson M.P., Hennig B., and Toborek M. Nicotine protects against arachidonic-acid-induced caspase activation, cytochrome c release and apoptosis of cultured spinal cord neurons. Journal of Neurochemistry 76 (2001) 1395-1403
18. German D.C., Schlusselberg D.S., and Woodward D.J. Three-dimensional computer reconstruction of midbrain dopaminergic neuronal populations: from mouse to man. Journal of Neural Transmission 57 (1983) 243-254
19. Gill S.S., Patel N.K., Hotton G.R., O'Sullivan K., McCarter R., Bunnage M., Brooks D.J., Svendsen C.N., and Heywood P. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nature Medicine 9 (2003) 589-595
20. Gorell J.M., Rybicki B.A., Johnson C.C., and Peterson E.L. Smoking and Parkinson's disease: a dose-response relationship. Neurology 52 (1999) 115-119
21. Hefti F., Melamed E., and Wurtman R.J. Partial lesions of the dopaminergic nigrostriatal system in rat brain: biochemical characterization. Brain Research 195 (1980) 123-137
22. Hejmadi M.V., Dajas-Bailador F., Barns S.M., Jones B., and Wonnacott S. Neuroprotection by nicotine against hypoxia-induced apoptosis in cortical cultures involves activation of multiple nicotinic acetylcholine receptor subtypes. Molecular and Cellular Neuroscience 24 (2003) 779-786
23. Janson A.M., Fuxe K., Agnati L.F., Kitayama I., Harfstrand A., Andersson K., and Goldstein M. Chronic nicotine treatment counteracts the disappearance of tyrosine-hydroxylase-immunoreactive nerve cell bodies, dendrites and terminals in the mesostriatal dopamine system of the male rat after partial hemitransection. Brain Research 455 (1988) 332-345
24. Janson A.M., Fuxe K., and Goldstein M. Differential effects of acute and chronic nicotine treatment on MPTP-(1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induced degeneration of nigrostriatal dopamine neurons in the black mouse. The Clinical Investigator 70 (1992) 232-238
25. Janson A.M., Meana J.J., Goiny M., and Herrera-Marschitz M. Chronic nicotine treatment counteracts the decrease in extracellular neostriatal dopamine induced by a unilateral transection at the mesodiencephalic junction in rats: a microdialysis study. Neuroscience Letters 134 (1991) 88-92
26. Jeyarasasingam, G., Quik, M., 1999a. Nicotine partially protects ventral mesencephalic cells from MPP+ neurotoxicity in vitro. Proceedings of the Society for Neuroscience.
27. Jeyarasasingam, G., Quik, M., 1999b. Nicotinic receptor mediated protection against dopaminergic neuron degeneration in mesencephalic cell cultures. Proceedings of the International Symposium on Nicotine.
28. Karler R., Calder L.D., Chaudhry I.A., and Turkanis S.A. Blockade of "reverse tolerance" to cocaine and amphetamine by MK-801. Life Science 45 (1989) 599-606
29. Kihara T., Shimohama S., Sawada H., Kimura J., Kume T., Kochiyama H., Maeda T., and Akaike A. Nicotinic receptor stimulation protects neurons against beta-amyloid toxicity. Annals of Neurology 42 (1997) 159-163
30. Li Y., King M.A., Grimes J., Smith N., de Fiebre C.M., and Meyer E.M. Alpha7 nicotinic receptor mediated protection against ethanol-induced cytotoxicity in PC12 cells. Brain Research 816 (1999) 225-228
31. Linert W., Bridge M.H., Huber M., Bjugstad K.B., Grossman S., and Arendash G.W. In vitro and in vivo studies investigating possible antioxidant actions of nicotine: relevance to Parkinson's and Alzheimer's diseases. Biochimica et Biophysica Acta 1454 (1999) 143-152
32. Lippiello P.M., Bencherif M., Gray J.A., Peters S., Grigoryan G., Hodges H., and Collins A.C. RJR-2403: a nicotinic agonist with CNS selectivity II. In vivo characterization. Journal of Pharmacology and Experimental Therapeutics 279 (1996) 1422-1429
33. Maggio R., Riva M., Vaglini F., Fornai F., Molteni R., Armogida M., Racagni G., and Corsini G.U. Nicotine prevents experimental parkinsonism in rodents and induces striatal increase of neurotrophic factors. Journal of Neurochemistry 71 (1998) 2439-2446
34. Morens D.M., Grandinetti A., Reed D., White L.R., and Ross G.W. Cigarette smoking and protection from Parkinson's disease: false association or etiologic clue?. Neurology 45 (1995) 1041-1051
35. Nakamizo T., Kawamata J., Yamashita H., Kanki R., Kihara T., Sawada H., Akaike A., and Shimohama S. Stimulation of nicotinic acetylcholine receptors protects motor neurons. Biochemical and Biophysical Research Communications 330 (2005) 1285-1289
36. Olanow C.W., and Tatton W.G. Etiology and pathogenesis of Parkinson's disease. Annual Reviews in Neuroscience 22 (1999) 123-144
37. O'Neill M.J., Moore N.A., McKinzie D.L., Keenan M., Wishart G., Shannon H.E., Murray T.K., O'Neill M.F., Tree B., Iyengar S., Hart J., Shaw D., Simmons R.M.A., Kalra A.B., Miles C., Baker S.R., Sher E., and Trickelbank M.D. Behavioural Profiling of Two Potent alpha-7 Nicotinic Acetylcholine Receptor Agonists (2002), Society for Neuroscience, New Orleans, USA
38. O'Neill M.J., Murray T.K., Lakics V., Visanji N.P., and Duty S. The role of neuronal nicotinic acetylcholine receptors in acute and chronic neurodegeneration. Current Drug Targets in CNS Neurological Disorders 1 (2002) 399-411
39. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates (1986), Academic Press, Sydney
40. Quik M., and Kulak J.M. Nicotine and nicotinic receptors; relevance to Parkinson's disease. Neurotoxicology 23 (2002) 581-594
41. Quik M., Parameswaran N., Bordia T., Bao S., Kim A., Tyndale R.F., Langston J.W., Di Monte D.A., and McCallum S.E. Chronic oral nicotine treatment protects against striatal degeneration in monkey brain (2005), Society For Neuroscience, Washington, DC
42. Robinson T.E., and Becker J.B. Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Research 396 (1986) 157-198
43. Ryan R.E., Ross S.A., Drago J., and Loiacono R.E. Dose-related neuroprotective effects of chronic nicotine in 6-hydroxydopamine treated rats, and loss of neuroprotection in alpha4 nicotinic receptor subunit knockout mice. British Journal of Pharmacology 132 (2001) 1650-1656
44. Salminen O., Murphy K.L., McIntosh J.M., Drago J., Marks M.J., Collins A.C., and Grady S.R. Subunit composition and pharmacology of two classes of striatal presynaptic nicotinic acetylcholine receptors mediating dopamine release in mice. Molecular Pharmacology 65 (2004) 1526-1535
45. Schapira A.H., and Olanow C.W. Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. Journal of the American Medical Association 291 (2004) 358-364
46. Shimohama S., Akaike A., and Kimura J. Nicotine-induced protection against glutamate cytotoxicity. Nicotinic cholinergic receptor-mediated inhibition of nitric oxide formation. Annals of the New York Academy of Sciences 777 (1996) 356-361
47. Shimohama S., and Kihara T. Nicotinic receptor-mediated protection against beta-amyloid neurotoxicity. Biological Psychiatry 49 3 (2001) 233-239
48. Soto-Otero R., Mendez-Alvarez E., Hermida-Ameijeiras A., Lopez-Real A.M., and Labandeira-Garcia J.L. Effects of (-)-nicotine and (-)-cotinine on 6-hydroxydopamine-induced oxidative stress and neurotoxicity: relevance for Parkinson's disease. Biochemical Pharmacology 64 (2002) 125-135
49. Stripling J.S., and Ellinwood Jr. E.H. Augmentation of the behavioral and electrophysiologic response to cocaine by chronic administration in the rat. Experimental Neurology 54 (1977) 546-564
50. Summers K.L., Lippiello P., and Giacobini E. A microdialysis study of the effects of the nicotinic agonist RJR-2403 on cortical release of acetylcholine and biogenic amines. Neurochemical Research 21 (1996) 1181-1186
51. Tizabi Y., Al-Namaeh M., Manaye K.F., and Taylor R.E. Protective effects of nicotine on ethanol-induced toxicity in cultured cerebellar granule cells. Neurotoxicology Research 5 (2003) 315-321
52. Tohgi H., Utsugisawa K., and Nagane Y. Protective effect of nicotine through nicotinic acetylcholine receptor alpha 7 on hypoxia-induced membrane disintegration and DNA fragmentation of cultured PC12 cells. Neuroscience Letters 285 (2000) 91-94
53. Yuan H., Sarre S., Ebinger G., and Michotte Y. Neuroprotective and neurotrophic effect of apomorphine in the striatal 6-OHDA-lesion rat model of Parkinson's disease. Brain Research 1026 (2004) 95-107
54. Yuan H., Sarre S., Ebinger G., and Michotte Y. Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease. Journal of Neuroscience Methods 144 (2005) 35-45
55. Zoli M., Moretti M., Zanardi A., McIntosh J.M., Clementi F., and Gotti C. Identification of the nicotinic receptor subtypes expressed on dopaminergic terminals in the rat striatum. Journal of Neuroscience 22 (2002) 8785-8789